國鼎「新冠口服藥」二期解盲成功 | NOWnews 今日新聞 | LINE TODAY

https://liff.line.me/1454987169-1WAXAP3K/v2/article/GgnQEmP?utm_source=lineshare

國鼎「新冠口服藥」二期解盲成功 | NOWnews 今日新聞 | LINE TODAY

興櫃股國鼎生技(4132)今(5)日停牌,公布旗下的新冠肺炎口服藥Antroquinonol二期臨床試驗解盲成功,康復率可達100%,將向美國FDA(美國食品藥品監督管理局)申請緊急授權(EUA)審查。另高端今也稱追打第三劑,可望對新型變異株Omicron增加保護力。 去年國鼎生技的新冠肺炎新藥Antroquinonol獲准可在美國、秘魯及阿根廷等地進行人體二期臨床試驗,該試驗是採隨機、雙盲、安慰

https://liff.line.me/1454987169-1WAXAP3K/v2/article/GgnQEmP?utm_source=lineshare
Past 31 days
Total Visit: 0
There are 0 fact-checking replies to the message
No response has been written yet. It is recommended to maintain a healthy skepticism towards it.
Add Cofacts as friend in LINE
Add Cofacts as friend in LINE
LINE 機器人
查謠言詐騙